Edition:
United States

Repros Therapeutics Inc (RPRX.OQ)

RPRX.OQ on NASDAQ Stock Exchange Capital Market

1.77USD
2 Dec 2016
Change (% chg)

-- (--)
Prev Close
$1.77
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
39,600
52-wk High
$3.48
52-wk Low
$0.80

Select another date:

Tue, Nov 8 2016

BRIEF-Repros Therapeutics reports loss per share of $0.17

* Repros Therapeutics In Reports third quarter 2016 financial results

BRIEF-Repros' secondary hypogonadism treatment filing accepted by European authorities

* Repros announces acceptance of dossier for Enclomiphene for secondary hypogonadism by European authorities

BRIEF-Repros provides mid-stage results showing positive outcomes for oral Proellex

* Repros provides phase 2 results showing positive outcomes for oral Proellex in women with moderate to severe Endometriosis

BRIEF-Repros says groups showed improvement in Enclomiphene study

* Repros provides six month interim results for Enclomiphene study in obese secondary Hypogonadal men

BRIEF-Repros Therapeutics - entered into a sales agreement with Ladenburg Thalmann & Co under which co may offer its shares of up to $10 million

* Entered into a sales agreement with Ladenburg Thalmann & Co under which co may offer its shares of up to $10 million Source text for Eikon: Further company coverage:

Select another date: